{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:33Z","timestamp":1790610813240,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Leptomeningeal metastasis (LM) is among the most severe complications in lung cancer patients, particularly for those without targetable gene mutations, who typically survive just 1\u20134\u00a0months. We present the case of a 68-year-old man with non-small cell lung cancer (NSCLC) and LM (pT1cN0M1b, stage IVB) whose primary lesion was early-stage with no other distant metastases. Genetic testing identified only a KRAS-G12V mutation. After neurological symptoms progressed following one cycle of pemetrexed, bevacizumab plus platinum-based chemotherapy, the patient underwent ventriculoperitoneal shunt placement and Ommaya reservoir implantation. Treatment with intrathecal pemetrexed via the Ommaya reservoir, combined with intravenous tislelizumab and carboplatin, resulted in 12\u00a0months of progression-free survival. For subsequent central nervous system progression involving both brain parenchymal metastasis and LM, we administered whole brain radiotherapy followed by second-line intrathecal thiotepa via Ommaya reservoir alongside tislelizumab and bevacizumab. This achieved continued shrinkage of brain lesions and neurological improvement. After ten cycles, thrombocytopenia necessitated switching to intrathecal methotrexate. Remarkably, the patient has survived nearly 29\u00a0months while maintaining good performance status and quality of life - to our knowledge, one of the longest reported survival for an NSCLC patient with LM harboring KRAS-G12V or other non-targetable mutations. This case suggests that combining ventriculoperitoneal shunt with Ommaya reservoir-delivered intrathecal chemotherapy may represent an effective therapeutic approach for LM patients.<\/jats:p>","DOI":"10.3389\/fphar.2025.1632369","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:39Z","timestamp":1761111159000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Extended survival in KRAS-G12V NSCLC with leptomeningeal metastasis through integrated intrathecal chemotherapy and systemic therapies"],"prefix":"10.3389","volume":"16","author":[{"given":"Yun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain penetration of lorlatinib: cumulative incidences of Cns and non-Cns progression with lorlatinib in patients with previously treated Alk-Positive non-small-cell lung cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Target Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3171\/2022.8.Jns221175","article-title":"Multidisciplinary management of patients with non-small cell lung cancer with leptomeningeal metastasis in the tyrosine kinase inhibitor era","volume":"138","author":"Chen","year":"2023","journal-title":"J. Neurosurg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","article-title":"Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from Egfr-mutant Nsclc\u2014a prospective, open-label, single-arm phase 1\/2 clinical trial (unique identifier: Chictr1800016615)","volume":"16","author":"Fan","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"102384","DOI":"10.1016\/j.esmoop.2024.102384","article-title":"Efficacy and safety of intrathecal pemetrexed for Tki-Failed leptomeningeal metastases from Egfr+ nsclc: an expanded, single-arm, phase Ii clinical trial","volume":"9","author":"Fan","year":"2024","journal-title":"ESMO Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.7150\/jca.27899","article-title":"Kras G12v mutation is an adverse prognostic factor of Chinese gastric cancer patients","volume":"10","author":"Fu","year":"2019","journal-title":"J. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1111\/cas.15035","article-title":"Trametinib overcomes Kras-G12v-Induced osimertinib resistance in a leptomeningeal carcinomatosis model of Egfr-Mutant lung cancer","volume":"112","author":"Fukuda","year":"2021","journal-title":"Cancer Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1215\/15228517-2007-059","article-title":"A multicenter phase ii trial of intrathecal topotecan in patients with meningeal malignancies","volume":"10","author":"Groves","year":"2008","journal-title":"Neuro Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"101106","DOI":"10.1016\/j.currproblcancer.2024.101106","article-title":"Current perspectives of kras in non-small cell lung cancer","volume":"51","author":"Harris","year":"2024","journal-title":"Curr. Probl. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/cancers12040837","article-title":"The inhibition of wnt restrain Kras(G12v)-Driven metastasis in non-small-cell lung cancer","volume":"12","author":"Hung","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/nop\/npad056","article-title":"Ventriculoperitoneal shunting with an on-Off valve for patients with leptomeningeal metastases and intracranial hypertension","volume":"11","author":"Huntoon","year":"2024","journal-title":"Neurooncol Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.2174\/0929867330666230508142657","article-title":"A review on the efficacy and safety of intrathecal administration of novel medications for leptomeningeal metastases in solid cancers","volume":"31","author":"Jafari","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12032-024-02401-w","article-title":"Revisiting intrathecal thiotepa: efficacy and safety in secondary cns malignancies","volume":"41","author":"Jamison","year":"2024","journal-title":"Med. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"C181","DOI":"10.4103\/0973-1482.200596","article-title":"Nimotuzumab treatment and outcome analysis in patients with leptomeningeal metastasis from nonsmall cell lung cancer","volume":"12","author":"Ju","year":"2016","journal-title":"J. Cancer Res. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12957-019-1595-7","article-title":"Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis","volume":"17","author":"Kim","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","article-title":"A phase I\/Ii study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (Her2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics","volume":"25","author":"Kumthekar","year":"2023","journal-title":"Neuro Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.jtho.2020.06.018","article-title":"Osimertinib improves overall survival in patients with Egfr-Mutated nsclc with leptomeningeal metastases regardless of T790m mutational status","volume":"15","author":"Lee","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.21037\/apm-19-521","article-title":"Treatment response to intrathecal chemotherapy with pemetrexed Via an ommaya reservoir in Egfr-Mutated leptomeningeal metastases from non-small cell lung cancer: a case report","volume":"9","author":"Li","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/j.cllc.2022.11.011","article-title":"Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed Via the ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: a prospective phase I study","volume":"24","author":"Li","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e20690","DOI":"10.1016\/j.heliyon.2023.e20690","article-title":"Afatinib overcoming resistance to icotinib and osimertinib in nsclc with leptomeningeal metastasis in patients with acquired Egfr L858r\/T790m or L858r\/S768i mutations: two case reports","volume":"9","author":"Li G.","year":"2023","journal-title":"Heliyon"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.21037\/apm-21-321","article-title":"Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor Exon 20 insertion mutation: a case report","volume":"11","author":"Ma","year":"2022","journal-title":"Ann. Palliat. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.21037\/apm-20-2086","article-title":"Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis","volume":"9","author":"Miao","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12987-021-00253-4","article-title":"Reference values for intracranial pressure and lumbar cerebrospinal fluid pressure: a systematic review","volume":"18","author":"Norager","year":"2021","journal-title":"Fluids Barriers CNS"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.Ccr-22-1585","article-title":"Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments","volume":"29","author":"Ozcan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-022-04118-0","article-title":"Intrathecal therapy for the management of Leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials","volume":"160","author":"Palmisciano","year":"2022","journal-title":"J. Neurooncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/ijc.30214","article-title":"Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single\u2010arm study","volume":"139","author":"Pan","year":"2016","journal-title":"Int. J. Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3389\/fonc.2019.00838","article-title":"A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from non-small-cell lung cancer","volume":"9","author":"Pan","year":"2019","journal-title":"Front. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1758835920937953","DOI":"10.1177\/1758835920937953","article-title":"Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-csf therapy for leptomeningeal metastases from solid tumors: a phase I\/Ii study","volume":"12","author":"Pan","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.18632\/oncotarget.5911","article-title":"Leptomeningeal metastasis in breast cancer - a systematic review","volume":"7","author":"Scott","year":"2016","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00701-021-04763-w","article-title":"Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis","volume":"164","author":"Su","year":"2022","journal-title":"Acta Neurochir. (Wien)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"116706","DOI":"10.1016\/j.jns.2020.116706","article-title":"Leptomeningeal metastasis from solid tumors","volume":"411","author":"Thakkar","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.2147\/ott.S164968","article-title":"Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2022.09.013","article-title":"Leptomeningeal metastases in non-small cell lung cancer: diagnosis and treatment","volume":"174","author":"Wang","year":"2022","journal-title":"Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.14791\/btrt.2022.0022","article-title":"Lumboperitoneal shunt combined with ommaya reservoir enables continued intraventricular chemotherapy for leptomeningeal metastasis with increased intracranial pressure","volume":"10","author":"Woo","year":"2022","journal-title":"Brain Tumor Res. Treat."},{"key":"B42","doi-asserted-by":"publisher","first-page":"Cns99","DOI":"10.2217\/cns-2022-0018","article-title":"Her2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen","volume":"12","author":"Wu","year":"2023","journal-title":"CNS Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3892\/ol.2016.4783","article-title":"Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: a pooled analysis","volume":"12","author":"Wu","year":"2016","journal-title":"Oncol. Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/jco.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the bloom study","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s42003-024-06209-2","article-title":"Identification and affinity enhancement of T-Cell receptor targeting a Kras(G12v) cancer neoantigen","volume":"7","author":"Zhang","year":"2024","journal-title":"Commun. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e795","DOI":"10.1097\/cad.0000000000001222","article-title":"Complete remission in leptomeningeal metastasis of nsclc with rare Egfr-Sept14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed","volume":"33","author":"Zheng","year":"2022","journal-title":"Anticancer Drugs"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1377451","DOI":"10.3389\/fonc.2024.1377451","article-title":"Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of Egfr-Mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review","volume":"14","author":"Zhong","year":"2024","journal-title":"Front. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12885-023-10806-5","article-title":"Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Cancer"},{"key":"B37","volume-title":"Ommaya reservoir","author":"Zubair","year":"2024"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1632369\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:43Z","timestamp":1761111163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1632369\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1632369"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1632369","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1632369"}}